FDA Removes ERA Embryofetal Toxicity REMS Requirements After Two Decades of Post-Market Pregnancy Data

A two-decade accumulation of human pregnancy data has led FDA to conclude that REMS-level controls are no longer necessary to manage embryofetal toxicity risk across the endothelin receptor antagonist class, a decision that directly changes prescribing, dispensing, and enrollment workflows for affected products. For regulatory affairs teams, the action is a concrete example of the agency exercising its authority to sunset risk management programs when post-market evidence no longer supports the original precautionary framework.

In April 2025, FDA eliminated REMS programs entirely for four ERA medicines: ambrisentan (Letairis and generics), macitentan-containing products (Opsumit and generics, Opsynvi), and aprocitentan (Tryvio). Elimination is substantive: prescribers, pharmacies, and healthcare facilities may now prescribe and dispense these agents without enrolling in or maintaining REMS participation. Patient enrollment requirements, where they previously existed, are also lifted.

Two additional ERA medicines received a narrower modification rather than full elimination. Bosentan (Tracleer and generics) and sparsentan (Filspari) retain REMS programs, but FDA approved modifications in fall 2025 to strip out the embryofetal toxicity components. Hepatotoxicity-related REMS requirements for both agents remain in effect, meaning dispensing controls tied to liver-risk monitoring are unchanged and compliance obligations persist.

The scientific basis for the change is explicit in FDA's communication. Original REMS requirements for EFT risk were derived from animal study findings. Longitudinal monitoring of clinical outcomes in patients exposed to ERA medicines during pregnancy did not produce a pattern of congenital malformations consistent with animal data, prompting the agency's reassessment. Critically, EFT risk language is not being removed from prescribing information: ERA medicines remain contraindicated in pregnancy, and labeling will continue to require pregnancy exclusion before treatment initiation and effective contraception during treatment.

For QA directors and regulatory affairs leads managing REMS portfolios, the operational read is immediate. Enrollment databases, dispensing checklists, and healthcare provider training materials tied to the eliminated REMS programs require revision. Facilities that have built EFT-specific REMS workflows into their 21 CFR Part 211 dispensing SOPs should initiate change control procedures to align documentation with the current regulatory status. For bosentan and sparsentan, a parallel review is warranted to confirm that updated REMS documents reflecting the approved modifications are in use and that hepatotoxicity controls remain fully intact.

FDA's stated position, that labeling alone is now adequate to communicate EFT risk for this class, sets a reference point for sponsors and regulatory teams evaluating whether other long-standing REMS programs remain proportionate to current post-market evidence.

Source: FDA Drugs RSS Feed via FDA.gov, 26 May 2026.